Business Context and Reporting Period
This Form 8-K is filed by Pluri Inc. (Pluristem Therapeutics Inc.) on October 6, 2008. The report addresses regulatory compliance regarding the company's continued listing on the Nasdaq Capital Market following recent equity financing activities.
Key Financial Metrics
- Shareholders' Equity: Reported as $2.33 million in the Form 10-K filed on September 29, 2008.
- Recent Capital Raises:
- September 22, 2008: Raised $1,035,000 via the sale of 900,000 shares and warrants for 675,000 shares.
- August 5-6, 2008: Raised $1,600,000 via the sale of 1,391,304 shares and warrants for 695,652 shares.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels.
Material Changes
The primary material change is the increase in shareholders' equity resulting from two private placement offerings completed in August and September 2008. These transactions were necessary to meet the Nasdaq Capital Market's minimum shareholders' equity requirement for continued listing.
Outlook and Management Commentary
Management confirms that, following the aforementioned offerings, the company is in full compliance with the shareholders' equity requirement for continued listing on the Nasdaq Capital Market as of the date of this report. No specific forward-looking guidance, risk factors, or unusual items are detailed in this specific filing.
Investor Verification Checklist
- Verify the total number of outstanding shares post-offering to assess dilution impact.
- Confirm the current shareholders' equity balance exceeds the Nasdaq minimum threshold.
- Review the terms of the warrants issued (exercise price and expiration) in the August and September transactions.
- Check the September 29, 2008 Form 10-K for detailed financial statements not included in this 8-K.